{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:18:01Z","timestamp":1792534681397,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T00:00:00Z","timestamp":1729382400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003358","name":"Gedeon Richter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40262-024-01431-x","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T07:01:54Z","timestamp":1729407714000},"page":"1501-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Coadministration of Cariprazine with a Moderate CYP3A4 Inhibitor in Patients with Schizophrenia: Implications for Dose Adjustment and Safety Monitoring"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0936-4911","authenticated-orcid":false,"given":"M\u00e1t\u00e9","family":"Szab\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Hujber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Hars\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Szatm\u00e1ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia B.","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Magyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Heged\u0171s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piroska","family":"Ratsk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"P\u00e1sztor M\u00e9sz\u00e1ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gota","family":"Barab\u00e1ssy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,20]]},"reference":[{"issue":"6","key":"1431_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cpt.1435","volume":"105","author":"A Tornio","year":"2019","unstructured":"Tornio A, Filppula AM, Niemi M, Backman JT. Clinical studies on drug\u2013drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther. 2019;105(6):1345\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"1431_CR2","unstructured":"FDA. VRAYLARTM (cariprazine) Capsules. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/204370lbl.pdf."},{"key":"1431_CR3","unstructured":"Reagila Summary of Product Characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/reagila-epar-product-information_en.pdf"},{"key":"1431_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","volume":"333","author":"B Kiss","year":"2010","unstructured":"Kiss B, Horv\u00e1th A, N\u00e9methy Z, Schmidt \u00c9, Laszlovszky I, Bugovics G, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333:328\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"1431_CR5","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. EMA. 2012 [cited 2024 May 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf"},{"key":"1431_CR6","unstructured":"Erythromycin Tablets BP 250 mg. Sovereign Medical."},{"issue":"6","key":"1431_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/000456329903600604","volume":"36","author":"J Van der Weide","year":"1999","unstructured":"Van der Weide J, Steijns LSW. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem. 1999;36(6):722\u20139.","journal-title":"Ann Clin Biochem"},{"key":"1431_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s13318-020-00650-4","volume":"46","author":"A Periclou","year":"2021","unstructured":"Periclou A, Phillips L, Ghahramani P, Kap\u00e1s M, Carrothers T, Khariton T. Population pharmacokinetics of cariprazine and its major metabolites. Eur J Drug Metab Pharmacokinet. 2021;46:53\u201369.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"1431_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s13318-020-00650-4","volume":"46","author":"A Periclou","year":"2021","unstructured":"Periclou A, Phillips L, Ghahramani P, Kap\u00e1s M, Carrothers T, Khariton T. Population pharmacokinetics of cariprazine and its major metabolites. Eur J Drug Metab Pharmacokinet. 2021;46(1):53\u201369.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1431_CR10","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation. EMA. 2011 [cited 2024 May 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf"},{"key":"1431_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson L, Dahl M, Dal\u00e9n P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111\u201322.","journal-title":"Br J Clin Pharmacol"},{"key":"1431_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2147\/NDT.S301225","volume":"17","author":"\u00c1 Barab\u00e1ssy","year":"2021","unstructured":"Barab\u00e1ssy \u00c1, Sebe B, Acsai K, Laszlovszky I, Szatm\u00e1ri B, Earley WR, et al. Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase ii\/iii studies. Neuropsychiatr Dis Treat. 2021;17:957\u201370.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1431_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2174\/138920008784746373","volume":"9","author":"L Urichuk","year":"2008","unstructured":"Urichuk L, Prior T, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug\u2013drug interactions. Curr Drug Metab. 2008;9:410\u20138.","journal-title":"Curr Drug Metab"},{"key":"1431_CR14","doi-asserted-by":"publisher","unstructured":"Soria-Chacartegui P, Villapalos-Garc\u00eda G, Zubiaur P, Abad-Santos F, Koller D. Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol. 2021;12:711940. https:\/\/doi.org\/10.3389\/fphar.2021.711940. PMID: 34335273; PMCID: PMC8316766.","DOI":"10.3389\/fphar.2021.711940"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01431-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:18:21Z","timestamp":1730297901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01431-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1431"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01431-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"16 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study was financed by Gedeon Richter Plc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors are employees of Gedeon Richter Plc., the originator of cariprazine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study data are owned by Gedeon Richter Plc (Budapest, Hungary). Parts of data can be made available upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study was conducted only in Bulgaria. Bulgarian Central Ethics Committee approved the Clinical Trial Application on 17 April 2019. The Ministry of Health granted approval on 23 March 2020 (with this approval \u2019full approval\u2019 was obtained for study conduct).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"ICH-E6 GCP guidelines were followed and written informed consent was obtained from all participants.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors participated in the writing, editing, and critical revision for intellectual content, and approved the final version of this manuscript. Specific roles: M\u00e1t\u00e9 Szab\u00f3 (Clinical Project Manager and Supervisor Medical Monitor), Zolt\u00e1n Hujber (Clinical Project Manager), Judit Hars\u00e1nyi (study design), Bal\u00e1zs Szatm\u00e1ri (data interpretation), Gabriella P\u00e1sztor M\u00e9sz\u00e1ros (Principal Analyst), Zsuzsanna Heged\u0171s and Piroska Ratsk\u00f3 (bioanalytical measurements), Gabriella Magyar (pharmacokinetics and associated statistical analysis), Zs\u00f3fia B. Dombi (writing assistance), \u00c1gota Barab\u00e1ssy (data interpretation, study design and writing assistance).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}